EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A baseline systemic inflammatory signature predicts anti-PD-1 response in advanced melanoma

Bruna Pereira Sorroche, Renan de Jesus Teixeira, Vinícius Gonçalves de Souza, Letícia Rafaela Ziquiel, Katiane Tostes, Caio Augusto Dantas Pereira, Iara Viana Vidigal Santana, Vinicius de Lima Vazquez, Lidia Maria Rebolho Batista Arantes

Clinical and Translational Oncology · 25.07.2026

DOI: 10.1007/s12094-026-04506-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Oncology, online erschienen am 25.07.2026. Verfasst von Bruna Pereira Sorroche und 8 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Oncology Research Center, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 1331, Barretos, 14784-400, Brazil. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, Conselho Nacional de Desenvolvimento Científico e Tecnológico, Hospital de Câncer de Barretos.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Reliable baseline biomarkers to predict response to immune checkpoint inhibitors (ICI) in advanced melanoma remain limited. We evaluated whether pre-treatment circulating inflammatory, hematologic, and molecular markers could identify patients most likely to benefit from anti-PD-1 therapy.

Methods

In this retrospective cohort study, 136 patients with unresectable stage III or metastatic stage IV melanoma treated with anti-PD-1-based immunotherapy were analyzed. Baseline plasma cytokines were quantified by cytometric bead array, hematologic parameters were obtained from routine blood counts, and molecular features were extracted from clinical records. Multivariable logistic regression was used to identify independent predictors of treatment response, and model discrimination was assessed by receiver operating characteristic analysis.

Results

Responders exhibited lower IL-6 levels, higher IL-10 levels, a lower IL-6/IL-10 ratio, higher erythrocyte counts, lower monocyte counts, greater PD-L1 positivity, and more frequent BRAF V600 mutations. In multivariable analysis, elevated monocyte counts (OR 4.57, 95% CI 1.67–13.86) and increased IL-6 levels (OR 2.70, 95% CI 1.08–7.21) independently predicted non-response, whereas higher IL-10 levels (OR 0.16, 95% CI 0.04–0.51) and BRAF V600 mutations (OR 0.32, 95% CI 0.13–0.76) predicted favorable response. The multivariable model demonstrated good discriminatory performance (AUC 0.783), with 82% sensitivity and 72% specificity.

Conclusions

Baseline systemic inflammatory and hematologic biomarkers independently predict anti-PD-1 response in advanced melanoma. Impact Readily accessible blood-based biomarkers may support treatment stratification and improve selection of patients most likely to benefit from immunotherapy. Prospective validation in independent cohorts is warranted.

Schlagwörter

Stichwörter der Autor:innen

CytokinesHematologic biomarkersImmune checkpoint inhibitorsMelanomaTreatment response

Autor:innen und Institutionen

  • Molecular Oncology Research Center, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 1331, Barretos, 14784-400, Brazil.
  • Department of Pathology, Barretos Cancer Hospital, Barretos, Brazil.
  • Department of Clinical Oncology, Barretos Cancer Hospital, Barretos, Brazil.
  • Melanoma, Sarcoma and Mesenchymal Tumors Surgery Department, Barretos Cancer Hospital, Barretos, Brazil.
  • Molecular Oncology Research Center, Barretos Cancer Hospital, Rua Antenor Duarte Villela, 1331, Barretos, 14784-400, Brazil. lirebolho@hotmail.com.

Förderung

  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Hospital de Câncer de Barretos
  • Hospital De Amor

Zitieren

APA

Pereira Sorroche, B., de Jesus Teixeira, R., Gonçalves de Souza, V., Ziquiel, L. R., Tostes, K., Dantas Pereira, C. A., Viana Vidigal Santana, I., de Lima Vazquez, V., & Rebolho Batista Arantes, L. M. (2026). A baseline systemic inflammatory signature predicts anti-PD-1 response in advanced melanoma. Clinical and Translational Oncology. https://doi.org/10.1007/s12094-026-04506-2

Vancouver

Pereira Sorroche B, de Jesus Teixeira R, Gonçalves de Souza V, Ziquiel LR, Tostes K, Dantas Pereira CA, et al. A baseline systemic inflammatory signature predicts anti-PD-1 response in advanced melanoma. Clinical and Translational Oncology. 2026. doi:10.1007/s12094-026-04506-2

BibTeX
@article{PereiraSorroche2026,
  author = {Pereira Sorroche, Bruna and de Jesus Teixeira, Renan and Gonçalves de Souza, Vinícius and Ziquiel, Letícia Rafaela and Tostes, Katiane and Dantas Pereira, Caio Augusto and Viana Vidigal Santana, Iara and de Lima Vazquez, Vinicius and Rebolho Batista Arantes, Lidia Maria},
  title = {A baseline systemic inflammatory signature predicts anti-PD-1 response in advanced melanoma},
  journal = {Clinical and Translational Oncology},
  year = {2026},
  doi = {10.1007/s12094-026-04506-2}
}
Kostenlos starten →